The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The treatment ...

Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The treatment for ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. CINCINNATI (AP) — Brynn Schulte nearly died ...

Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or ...

A phase 2 clinical trial has demonstrated that pomalidomide, used to treat bone marrow cancer, is safe and effective for managing hereditary hemorrhagic telangiectasia, a rare genetic bleeding ...

World Haemophilia Day 2025: Haemophilia is a genetic bleeding disorder that occurs rarely due to deficiencies in clotting factors, leading to unheeded or less bleeding, joint pain, and other ...

The Food and Drug Administration approved Pfizer's treatment for a rare genetic bleeding disorder, making it the company's first gene therapy to win clearance in the U.S. The agency greenlighted the ...

The treatment for hemophilia A could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for a less common type of the bleeding disorder called ...

Stream San Diego News for free, 24/7, wherever you are with NBC 7. The treatment will be available by prescription to eligible patients this quarter, a Pfizer spokesperson told CNBC. It has a hefty $3 ...